OB 318

Drug Profile

OB 318

Alternative Names: OB-318

Latest Information Update: 26 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Oneness Biotech
  • Class Anti-inflammatories; Antineoplastics; Herbal medicines; Traditional-Chinese-medicine
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; MTOR protein inhibitors; Proto oncogene protein c-akt inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Hepatocellular carcinoma

Most Recent Events

  • 28 Apr 2016 Phase-I clinical trials in Hepatocellular carcinoma in Taiwan (PO) before April 2016
  • 28 Apr 2016 Phase-I clinical trials in Hepatocellular carcinoma in USA (PO) before April 2016
  • 02 Dec 2015 Oneness Biotech receives patent allowance for OB318 in Europe, Taiwan, Japan and China
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top